Neutrophil-lymphocyte ratio for predicting survival in sarcomatoid kidney cancer

A recent study of 230 patients with sarcomatoid renal cell carcinoma (RCC) investigated pre-surgery neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio as biomarkers for the prediction of survival. Neutrophil-lymphocyte ratio was assessed 1 to 8 weeks after surgery, and percentage change from pre- to post-surgery was calculated. Pre-surgery neutrophil-lymphocyte ratio was a significant predictor of […]

read more

GRANT score: A new tool to predict survival in kidney cancer patients

A recent study, published in Scientific Reports last month, describes the validation of a new scoring system for renal cell carcinoma (RCC) called GRade, Age, Nodes and Tumour (GRANT). GRANT can be used to predict survival of RCC patients who have had a nephrectomy. In this study, GRANT was validated in over 73,000 kidney cancer […]

read more

Right-sided kidney tumours have better outcomes

In a recent paper published in Cancer Medicine from researchers in Boston, USA, people with a large (10 cm or larger) renal cell carcinoma (RCC) tumour on their right kidney had a significant 15% decreased risk of death and better cancer-specific survival than left-sided RCC. Read more in Renal & Urology News here

read more

Comparing long-term outcomes for partial and radical nephrectomy

Using the National Cancer Database, 3009 patients with low stage renal cell carcinoma (RCC) were identified as having undergone radical (2454 patients) or partial (555 patients) nephrectomy and were younger than 50 years. Median follow-up was 108.6 months during which 297 patients (12.1%) in the radical nephrectomy arm and 58 patients (10.5%) in the partial nephrectomy […]

read more

Nivolumab demonstrates long term survival in advanced kidney cancer

A new study published in JAMA Oncology shows that treatment with nivolumab in previously treated patients increased 5-year survival rates for those with advanced melanoma, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC). Five -year survival rates were analysed in 270 patients with either melanoma, RCC or NSCLC in a phase 1 clinical […]

read more

Extended duration of active surveillance of small renal masses

A recent study published in the Journal of Urology evaluated the outcomes of 103 patients with small renal masses (<6 cm) who were on active surveillance. The patients were followed for a median of 55.5 months, and in that time only 1% died of metastatic renal cell carcinoma (RCC). Of the 103 patients, 51.5% survived […]

read more

Elderly kidney cancer patients benefit from targeted therapies

Elderly patients with metastatic renal cell carcinoma (RCC) are often underrepresented in clinical trials to treat the kidney cancer. However, according to a recent study published in JAMA Network Open Thirteen years of data were analysed from Medicare patients in the USA. Patients who received targeted therapies had more complex medical needs than those who […]

read more

Long-term surveillance of small renal masses is safe

In a recent study published in Journal of Urology and involving over 100 mostly older patients, almost all of the patients with small kidney tumours never developed advanced cancer or died of the disease during more than 4 years of follow-up in active surveillance. More than half of the patients remained alive without metastatic disease […]

read more

Percutaneous ablation for localised kidney tumours

A recent study reported in European Urology by investigators at the Mayo Clinic in Rochester, Minnesota, USA compared partial nephrectomy with percutaneous ablation (radiofrequency ablation or cryoablation) in the treatment of 1422 patients with localised renal tumours, stage cT1. Patients were followed for at least 6 years. There were no significant differences in local recurrence, […]

read more

ICR cancer drug programme aims to deliver a step change in cancer treatment

The world’s first ‘Darwinian’ cancer drug programme was launched by the Institute of Cancer Research (ICR), and aims to deliver a step change in cancer treatment. The programme will be run from the ICR’s £75 million state-of-the-art Centre for Cancer Drug Discovery in London. The new cancer drug programme will harness evolutionary science to tackle […]

read more
Showing 11 to 20 of 67 results
  TOP